

BREATHTEC BIOMEDICAL INC.

Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2

Breathtec Biomedical Appoints Experienced Product Development and Regulatory Consultant

VANCOUVER, BRITISH COLUMBIA – February 22, 2016 – [Breathtec Biomedical Inc.](http://www.breathtecbiomedical.com) (CSE: BTH) (CNSX: BTH) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that Mr. Guy LaTorre has been appointed as an advisor to assist in ongoing product development and licensing matters.

Mr. LaTorre will work closely with the University of Florida based product development team at the Yost Research Group, and will assist the team in streamlining regulatory compliance and product licensing applications.

“The next 18 months represent a very exciting period for Breathtec,” states Company President, Mr. Kal Malhi. “We are excited to have Guy join our team and believe that his experience and leadership will be instrumental in the Company’s near and long-term evolution and growth as we move toward solidifying ourselves as one of Canada’s leading companies in the exciting breath testing area of medical diagnostics.”

Mr. LaTorre brings over 25 years of experience in the development and commercialization of medical devices and consumer products in a startup company environment. Guy was a co-founder and Vice President of Business Development at Novamin Technology Inc. where he was responsible for identifying and managing the Company’s relationships with its key clients in the dental products field, including product development of in-office and at-home use products using the company’s proprietary ingredient. In that role, he formed and managed product development partnerships between NTI and the leading marketers of professional dental products, including Dentsply Corp, 3M Corp, Sultan Healthcare, Sunstar and others until the company was sold to GlaxoSmithKline (GSK) in 2010 for USD \$135 million.

Previously, Guy was the Director of Scientific Affairs at USBiomaterials Corp. which developed and sold synthetic bone grafting products for use in dental, head, neck and orthopedic surgeries. His responsibilities also included product development, manufacturing and business development activities. Prior to USBiomaterials, Guy was the Laboratory Manager of the University of Florida Advanced Materials Research Center where he was responsible for the managed transfer of licensed university technologies to private startup companies. Guy has been author or co-author of over fifty scientific publications and holds seven US patents with associated filings worldwide.

For more information, please visit: www.breathtecbiomedical.com.

ON BEHALF OF THE BOARD

"Kal Malhi"
President & Director

For further information, please contact:

CORE Capital Partners

Telephone: 604-566-9233

Email: investors@ccpartnersinc.com

Website: www.breathtecbiomedical.com

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.